GEN Highlights

Fiercebiotech News

  • ElevateBio reels in $170M to push 6 cell, gene therapy programs by Amirah Al Idrus (2020/03/31 02:58)
    Barely a year after launching with $150 million to build cell and gene therapy companies, ElevateBio is at it again. This time, it’s picking up another $170 million to propel six programs into the clinic and get its centralized R&D and manufacturing hub up and running.
  • COVID-19: Bio researchers race to repurpose everything from antiviral to anticancer discoveries by Arlene Weintraub (2020/03/30 18:18)
    Several academic institutions and biotech startups are stepping up with ideas of how to take existing research and pivot it towards potential solutions to COVID-19. It may take several months for these efforts to bear fruit, at which point this pandemic may have ended, but the scientists leading the charge believe their discoveries will help fend off future outbreaks.
  • ACC: Regeneron's Praluent sidekick cuts cholesterol in half—even in hard-to-treat patients by Amirah Al Idrus (2020/03/30 14:27)
    Regeneron revealed last summer that its latest cholesterol fighter, evinacumab, cut “bad” cholesterol in half for patients with a rare genetic disorder. Now, in full results presented virtually at the annual meeting of the American College of Cardiology (ACC), together with the World Congress of Cardiology, the drug did even better in a group of particularly hard to treat patients.
  • Battelle deploys decontamination system for reusing N95 masks by Conor Hale (2020/03/30 13:52)
    Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for personal protective equipment, allowing healthcare workers to clean and reuse scarce N95 respirator masks.
  • J&J, BARDA commit $1B to COVID-19 vaccine R&D by Nick Paul (2020/03/30 12:13)
    Johnson & Johnson has joined with a U.S. government agency to commit $1 billion to development of a COVID-19 vaccine. J&J plans to have a vaccine in the clinic by September, win emergency use authorization early next year and add capacity to make more than 1 billion doses. 
  • COVID-19 causes Moderna to pause a clutch of clinical trials by Nick Paul (2020/03/30 10:24)
    Moderna has become the latest company to hit pause on clinical trials in response to the COVID-19 pandemic. The biotech, which is leading efforts to develop a COVID-19 vaccine, is pausing enrollment in some infectious and rare disease trials while continuing to try to add patients to its cancer studies.
  • Aveo gives up on ficlatuzumab in acute myeloid leukemia, citing COVID-19 by Ben Adams (2020/03/30 09:36)
    Back in 2012, Aveo announced that its second most advanced asset, ficlatuzumab, had flopped in a midstage cancer test; for years, we heard nothing about this drug.
  • GigaGen jumps into COVID-19 arena with polyclonal antibodies by Amirah Al Idrus (2020/03/30 02:05)
    Mining the blood of recovered patients for treatments during a pandemic isn’t a new idea. Takeda and Grifols are already doing it, working on antibody-rich drugs made from the plasma of patients who have fought off COVID-19 infection. GigaGen thinks its approach could be even better.
  • ACC: MyoKardia's mavacamten reduces heart stress signs in targeted biomarker study by Conor Hale (2020/03/29 20:11)
    The former Fierce 15 winner delivered new cardiac biomarker data showing its late-phase mavacamten compound can help improve signs of heart stress and injury in hypertrophic cardiomyopathy.
  • ACC: 10-year coronary stent outcomes similar to bypass surgery, but less durable by Conor Hale (2020/03/29 16:48)
    In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years—as well as in cases of heart attack or stroke—between people that had received a drug-eluting stent for their blocked coronary artery compared with those who underwent standard bypass surgery.

Google News:Health